Plain-English translation of NCT05994365 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thyroid Neoplasms research guide →This trial is testing Anlotinib hydrochloride capsules to see if it can help people with advanced thyroid cancer that no longer responds to radioactive iodine treatment. Researchers want to understand how well this medication works and how safe it is in real-world situations—that is, among a wide range of patients outside of strict research settings. The study will also track how people respond who don't receive this treatment, to compare outcomes.
Some people with advanced thyroid cancer stop responding to radioactive iodine, the standard first-line treatment, leaving them with limited options. This trial exists to find out whether this medication can help slow or stop cancer growth in patients for whom radioactive iodine no longer works.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, you would take the medication by mouth once daily for 2 weeks, then take a 1-week break (this 3-week cycle repeats). You'll have regular check-ups and blood tests to monitor how well the treatment is working and watch for side effects. If you join the comparison group, researchers will collect information from your medical records about your cancer and treatment outcomes over time, either looking back at past records or following you forward—no medication is given in this group.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China